Advertisement
Research Article

Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis

  • Ian Ford mail,

    To whom correspondence should be addressed. E-mail: ian@stats.gla.ac.uk

    Affiliation: Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland

    X
  • Vladimir Bezlyak,

    Affiliation: Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland

    X
  • David J Stott,

    Affiliation: Academic Section of Geriatric Medicine, Cardiovascular Division, University of Glasgow, Glasgow, Scotland

    X
  • Naveed Sattar,

    Affiliation: Department of Vascular Biochemistry, North Glasgow Division, Greater Glasgow Health Board, Glasgow, Scotland

    X
  • Chris J Packard,

    Affiliation: Department of Vascular Biochemistry, North Glasgow Division, Greater Glasgow Health Board, Glasgow, Scotland

    X
  • Ivan Perry,

    Affiliation: Department of Pharmacology and Therapeutics, Cork University Hospital, Wilton, Cork, Ireland

    X
  • Brendan M Buckley,

    Affiliation: Department of Pharmacology and Therapeutics, Cork University Hospital, Wilton, Cork, Ireland

    X
  • J. Wouter Jukema,

    Affiliation: Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Anton J. M de Craen,

    Affiliation: Section of Gerontology and Geriatrics, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Rudi G. J Westendorp,

    Affiliation: Section of Gerontology and Geriatrics, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • James Shepherd

    Affiliation: Department of Vascular Biochemistry, North Glasgow Division, Greater Glasgow Health Board, Glasgow, Scotland

    X
  • Published: January 20, 2009
  • DOI: 10.1371/journal.pmed.1000016

Reader Comments (1)

Post a new comment on this article

Preventing 90% of ESRD: Why Is It Still A Secret?

Posted by plosmedicine on 31 Mar 2009 at 00:34 GMT

Author: David Moskowitz MD FACP
Position: CEO, Chief Medical Officer
Institution: GenoMed, Inc.
E-mail: dwmoskowitz@genomed.com
Submitted Date: January 21, 2009
Published Date: January 26, 2009
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

Dialysis and transplantation are a $35 billion a year industry in the US alone. End-stage renal disease (ESRD) funds all nephrologists and transplant surgeons, whether in academia or private practice, as well as tens of thousands of dialysis nurses and Medicare/National Health Service bureaucrats throughout the developed world.

The payment scheme for ESRD is already Single Payer in every country where it's funded.

ESRD evidently supports too many salaries to acknowledge a cure (1) even after one has been found (2).

In light of this glaring example, taxpayers--and Baby Boomers in particular--need to rethink whose side healthcare is really on. I'm sorry to say, it's not the patient's.

References
1. Moskowitz, DW. Promoting dialysis alternative. Letter. ACP Observer, Dec. 2006 (http://www.acponline.org/...)

2. Moskowitz DW. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Ther. 2002;4(4):519-32. PMID: 12396747.

Competing interests declared: CEO of GenoMed, a Next Generation Disease Management company.